ArticleContemporary oncology (Poznan, Poland)2025
High expression of the eukaryotic initiation factors eIF4a and eIF4e in retinoblastoma.
Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Retinoblastoma is a malignant, intraocular tumor which deve-lops within the first three years of life and has a variable prognosis. Aberrant expression of eukaryotic initiation factors (eIFs) has been reported in a variety of tumor entities, but there is a lack of data regarding eIF expression in retinoblastoma. Material and methods: We analyzed the expression of eIF4a and eIF4e in 30 retinoblastomas and samples of other ocular diseases via immunohisto-chemistry. Via western blot, we determined the expression of eIF4a and eIF4e in the two retinoblastoma cell lines WERI-Rb1 and Y79. Furthermore, we evaluated the influence of the eIF inhibitor 4EGI-1 on the cell viabi-lity of both cancer cell lines. Results: In this study, we observed increased expression of eIF4a and eIF4e in retinoblastoma samples compared to other ocular diseases. We also found that both proteins are expressed in the retinoblastoma cell lines WERI-Rb1 and Y79 and that their expression is independent of treatment with the eIF inhibitor 4EGI-1. However, inhibition of eIF function via 4EGI-1 reduced the cell viability of both cell lines in a dose- and time-dependent manner. Conclusion: We provide evidence that eIF4a and eIF4e are overexpressed in retinoblastoma and that their inhibition might represent a therapeutic target for the therapy of retinoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.